The bacterium S. aureus causes a range of serious infections in humans. It is responsible for approximately 16,000 deaths annually in Europe and 19,000 in the US. Additional studies suggest at least EUR 380 million annual European costs attributable to S. aureus, as well as several billion USD per annum in the US . The emergence of highly antibiotic resistant S. aureus strains, such as MRSA (Methicillin-resistant S. aureus), is creating a serious public health threat around the world, and an increasing economic burden. As recent vaccine candidates have not proven effective in large human clinical studies, there continues to be a high unmet medical need.

The pan-European BELLEROPHON Project is comprised of four European institutions involved in vaccine development, each contributing specialist expertise and technology. It includes Imaxio, a French biotech company focused in immunology and which has coordinated the grant application, and the Jenner Institute at Oxford University, UK, an academic institution with key expertise on S. aureus antigens and viral vector delivery systems and which will coordinate the overall project.

The European Vaccine Initiative is the third partner, assisting with the project management tasks and advising on production and clinical aspects of the project. The fourth member is Preclin Biosystems, a Swiss contract research organization that has a strong expertise in preclinical efficacy models for infectious diseases. 

 

This project has been funded with support from the European Commission under Grant agreement no: 601783

This website reflects the views only of the author, and the Commission cannot be held responsible for any use which may be made of the information contained therein.


News

15 September 2016

VAC2VAC project website goes live

VAC2VAC is a wide ranging collaborative research project funded by IMI2 which aims to develop and validate quality testing approaches for both human and veterinary vaccines using non animal methods.  

The initiative  that  started  on  1  March 2016 aims  to  provide  the  data  to  support  the ‘Consistency Approach’ for quality control of established vaccines.  More information on the project and on the participants can now be found under the following link: www.vac2vac.eu.

09 September 2016

EVI Annual Report 2015 now available

The EVI 2015 Annual Report provides a detailed insight into all of EVI's activities, projects, important meetings etc.  We hope you will find it not only enlightening, but interesting reading.

18 July 2016

BELLEROPHON Annual Meeting 2016

This year’s BELLEROPHON annual meeting took place 07-08 July in Heidelberg, Germany.  Staying at the ‘Internationales Wissenschaftsforum’ in the old town of Heidelberg allowed the participants to discuss the scientific progress in a charming and pleasant atmosphere.